Shu-Nan Qi Selected Research

Radiotherapy

3/2024	Treatment outcome, toxicity, and quality of life of patients with bronchus-associated lymphoid tissue lymphoma.
1/2024	Multicenter phase II study of moderate low-dose radiotherapy in indolent non-Hodgkin lymphoma: CLCG-iNHL-01 protocol.
11/2023	Tislelizumab and radiation therapy in low-risk early-stage extranodal natural killer/T-cell lymphoma, nasal type: a phase II study protocol.
11/2023	Decreased lymphoma-related deaths and improved long-term relative survival with radiotherapy for early-stage diffuse large B-cell lymphoma in the rituximab era.
7/2023	Effects of gross tumor volume and radiation dose on survival and locoregional recurrence in early-stage extranodal NK/T-cell lymphoma treated with intensity-modulated radiation therapy.
1/2023	Evidence of cure for extranodal nasal-type natural killer/T-cell lymphoma with current treatment: an analysis of the CLCG database.
1/2023	Dose-Volume Predictors for Radiation Esophagitis in Patients With Breast Cancer Undergoing Hypofractionated Regional Nodal Radiation Therapy.
1/2023	Radiation-Induced Hypothyroidism in Patients With Breast Cancer After Hypofractionated Radiation Therapy: A Prospective Cohort Study.
1/2023	Assessment of delivered dose in prostate cancer patients treated with ultra-hypofractionated radiotherapy on 1.5-Tesla MR-Linac.
12/2022	The safety of an MRI simulation-guided boost after short-course preoperative radiotherapy for unresectable rectal cancer (SUNRISE): interim analysis of a randomized phase II trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shu-Nan Qi Research Topics

Disease

19	Lymphoma (Lymphomas) 03/2024 - 01/2017
14	Neoplasms (Cancer) 01/2024 - 08/2007
14	Breast Neoplasms (Breast Cancer) 01/2023 - 01/2019
12	T-Cell Lymphoma (Lymphoma, T Cell) 01/2021 - 11/2009
5	Extranodal NK-T-Cell Lymphoma 11/2023 - 03/2013
4	Rectal Neoplasms (Rectal Cancer) 12/2022 - 09/2020
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2023 - 10/2016
2	Neutropenia 01/2018 - 08/2007
2	Nasopharyngeal Carcinoma 03/2009 - 08/2007
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2024
1	Stomach Neoplasms (Stomach Cancer) 01/2024
1	Adenocarcinoma 01/2024
1	Esophagitis 01/2023
1	Hypothyroidism 01/2023
1	Triple Negative Breast Neoplasms 01/2023
1	Prostatic Neoplasms (Prostate Cancer) 01/2023
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 10/2022
1	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 01/2022
1	Anemia 01/2018
1	Thrombocytopenia (Thrombopenia) 01/2018
1	B-Cell Lymphoma (Lymphoma, B Cell) 04/2013
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 03/2013
1	Mucositis 03/2009

Drug/Important Bio-Agent (IBA)

5	AnthracyclinesIBA 01/2023 - 12/2018
4	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 09/2023 - 01/2018
4	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 08/2007
2	Biomarkers (Surrogate Marker)IBA 01/2024 - 01/2023
2	Asparaginase (Elspar)FDA Link 11/2023 - 10/2018
2	Rituximab (Mabthera)FDA Link 11/2023 - 10/2020
2	Gemcitabine FDA Link 01/2022 - 01/2018
2	Guanosine Diphosphate (GDP)IBA 01/2022 - 01/2018
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 01/2018
2	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2013 - 03/2013
2	Docetaxel (Taxotere)FDA Link 03/2009 - 08/2007
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 02/2024
1	Immune Checkpoint InhibitorsIBA 11/2023
1	tislelizumabIBA 11/2023
1	N- (2- amino- 5- fluorobenzyl)- 4- (N- (pyridine- 3- acrylyl)aminomethyl)benzamideIBA 01/2022
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2021
1	Capecitabine (Xeloda)FDA Link 11/2021
1	Contrast MediaIBA 09/2020
1	Trastuzumab (Herceptin)FDA Link 01/2020
1	ErbB Receptors (EGF Receptor)IBA 01/2020
1	Fluorouracil (Carac)FDA LinkGeneric 08/2007

Therapy/Procedure

37	Radiotherapy 03/2024 - 11/2009
17	Drug Therapy (Chemotherapy) 11/2023 - 11/2009
6	Therapeutics 11/2023 - 01/2020
6	Mastectomy (Mammectomy) 01/2023 - 01/2020
6	Segmental Mastectomy (Lumpectomy) 01/2023 - 01/2020
5	Chemoradiotherapy 12/2022 - 08/2007
3	Neoadjuvant Therapy 01/2024 - 11/2021
2	Adjuvant Chemotherapy 10/2022 - 01/2020
2	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 09/2020 - 03/2012
2	Induction Chemotherapy 03/2009 - 08/2007
1	Lymph Node Excision (Lymph Node Dissection) 01/2024
1	Consolidation Chemotherapy 01/2024
1	Modified Radical Mastectomy (Mastectomy, Modified) 11/2020
1	Combination Drug Therapy (Combination Chemotherapy) 03/2012